Internal standards for therapeutic drug monitoring of potential COVID-19 drugs
Many laboratories and hospitals around the world are carrying out studies to find a solution against the spread of COVID-19 virus. Several drugs are on the test bench such as Hydroxychloroquine, Favipiravir or Remdesivir. Used alone or in combination with other drugs, these molecules demonstrate promising results. In order to develop and set up dosage methods, e.g. to determine the optimal doses, clinical studies based on therapeutic drug monitoring by LC-MS will be needed.
An Europe-wide clinical trial, called "Discovery", was launched to test four experimental treatments for COVID-19, including the following compounds: Remdesivir, Lopinavir and Ritonavir, Hydroxychloroquine. This trial will also complement the data that will be collected during another international clinical trial, called "Solidarity". Shimadzu and Alsachim are supporting these clinical trials by providing internal standards for therapeutic drug monitoring of these potential anti-COVID-19 drugs.
|Related Drug||Product Name||Pack of 1mg|
Lopinavir and Ritonavir
Remdesivir and GS 441524
(Active Metabolites of Nucleoside
|[13C6]-Remdesivir (Mixture of Diastereoisomers)||ALC-C8854-01|
GS 441524 / CAS 1191237-69-0
|Chloroquine and Hydroxychloroquine||
|[2H5]-Chloroquine oxalate salt||ALC-C5023-01|
|[2H5]-Hydroxychloroquine dioxalate salt||ALC-C6422-01|
|[2H5]-Desethylchloroquine dioxalate salt||ALC-C2453-01|
|Nafamostat Mesylate||Nafamostat Mesylate||ALC-C8848-01|
All products are delivered with a detailed Certificate of Analysis